Developer docs
API playgroundTry for free, no card

Search company profiles

inHEART

Full company profile

uuid0000vxz

Namestring
inHEART
Legal namestring
inHEART
Company typeenum
Private
Founded yearint
2017
Descriptiontext

inHEART is a privately-held French medical device software company, spun off in July 2017 from IHU LIRYC (a leading cardiac electrophysiology research institute in Bordeaux), that develops an AI-enabled digital twin of the human heart for image-guided catheter ablation procedures. The company's flagship inHEART MODELS software suite ingests pre-procedural CT and MR images, applies a proprietary AI segmentation algorithm, and produces interactive 3D cardiac models that visualize scar tissue, wall thickness, and critical isthmuses, then integrates with all major electroanatomic mapping systems (Carto, Rhythmia, EnSite) for intraprocedural guidance. The technology is clinically validated by 60+ peer-reviewed publications, FDA 510(k) cleared (including a March 2024 clearance for first-of-its-kind fully automated CT segmentation), CE certified under MDR 2017/745, and registered in the UK, Australia, and Switzerland.

The commercial model is enterprise SaaS-style software licensing sold directly to tertiary and quaternary cardiac electrophysiology centers, with a quote-based pricing structure and recurring subscription mechanics. Cumulative case support exceeds 7,500 across more than 300 partner hospitals in over 40 countries, with named reference sites including MUSC Health, RHÖN KLINIKUM, Brigham and Women's, Hartford Healthcare, Hôpitaux de la Timone, and Nippon Medical School. Distribution is hybrid: direct sales in the US and EU, regional distributors (Medical Horizons in Italy), and a May 2024 global distribution agreement with Circle Cardiovascular Imaging that is the primary vehicle for Asia-Pacific and Middle East expansion.

The business is funded by approximately $15.7M in equity and grant funding across seed, Series A, and follow-on rounds, with Vesalius Biocapital IV and Elaia Partners as lead institutional investors. Revenue is not publicly disclosed. Current strategic priorities include scaling the commercial core, building predictive AI product lines for sudden cardiac death, cardioembolic stroke, and heart failure (supported by the MEDITWIN and TALENT consortia), and pursuing global regulatory clearance to enable channel-driven geographic expansion beyond the existing US and EU footprint.

Short descriptiontext

inHEART develops AI-enabled digital twin software that converts cardiac CT and MR images into interactive 3D models for image-guided ablation procedures, sold to cardiac electrophysiology centers in over 40 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPessac, France
HQ citystring
Pessac
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac imaging software, electrophysiology solutions, digital twin technology, cardiac ablation planning, medical imaging AI
Industry2 codes
PRIMARYHLAKABAC
Electrophysiology (Heart Rhythm)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Computer Systems Design and Related Services54151
  • Diagnostic Imaging Centers621512
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Health Services8000
  • Services-Computer Integrated Systems Design7373
Product category
Cardiac Electrophysiology Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software Licensing - Therapeutic Solutions
TypeSubscription Recurring
Description

AI-driven digital twin software for image-guided cardiac ablation procedures, sold to hospitals and cardiac electrophysiology centers. Revenue derived from software licenses for the inHEART MODELS suite enabling 3D visualization and analysis for pre-procedural planning and intraprocedural guidance.

inheartmedical.com
2Predictive Software Models (Development Stage)
TypeSubscription Recurring
Description

New product verticals under development for AI-driven predictive software models for sudden cardiac death and cardio-embolic stroke, as well as therapeutic software for heart failure patients.

inheartmedical.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

inHEART provides a cloud-based SaaS platform, inHEART MODELS, that uses proprietary AI segmentation algorithms to transform cardiac CT and MR images into interactive 3D digital twin models for pre-procedural planning and intraprocedural guidance of catheter ablation procedures treating arrhythmias such as ventricular tachycardia (VT), atrial fibrillation (AF), and cardioneuroablation. The software integrates with all major electroanatomic mapping (EAM) systems (Carto, Rhythmia, EnSite) and is licensed to hospitals and cardiac electrophysiology centers under a subscription-based model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces procedure time by 60% (from 5 hours to less than 2 hours)
+2 more records
Product overview1 text field

inHEART delivers the world's most advanced AI-enabled digital twin of the heart through a cloud-based SaaS platform. The core offering is the inHEART MODELS software suite that creates interactive 3D models from CT and MR images for image-guided cardiac ablation planning. The platform includes AI-driven automated segmentation capabilities and integrates with all major electroanatomic mapping (EAM) systems. Current commercial products include therapeutic solutions for VT ablation, atrial fibrillation, and cardioneural ablation. Development underway includes predictive models for sudden cardiac death, cardio-embolic stroke, and heart failure. The company operates through the MEDITWIN and TALENT consortia for preventive cardiac care solutions. Available in US (FDA 510(k) cleared) and EU (CE MDR certified) markets.

Product and service1 record
1inHEART MODELS (Digital Twin of the Heart)
CategoryCardiac Electrophysiology Software
Description

AI-enabled cloud-based software suite that creates interactive 3D digital twin models of the heart from CT and MR images, providing unprecedented anatomical detail including scar visualization, wall thickness, tissue characteristics, and critical isthmus identification for personalized image-guided cardiac ablation planning. Licensed to hospitals and cardiac electrophysiology centers on a subscription basis and integrates with all major electroanatomic mapping (EAM) systems including Carto, Rhythmia, and EnSite.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-16
Description

Global distribution agreement enabling Circle to promote and market inHEART's AI-enabled digital twin through Circle's worldwide sales network. Partnership enables rapid global commercialization and particularly strengthens Asia-Pacific market presence.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-11
Description

MEDITWIN is a 5-year multidisciplinary consortium (2024-2029) evaluating personalized digital twins in healthcare. inHEART focuses on sudden cardiac death prevention using AI-based digital twin technology for risk stratification. Supported by French government.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-11
Description

inHEART is a spin-off company of IHU Liryc, the cardiac electrophysiology institute. Long-standing research and development partnership for cardiac imaging innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-11
Description

Collaboration with 9 academic, hospital, and industrial partners to screen for Cardioembolic Stroke risk using AI-based digital twins via chest CT and ECG. Supported by French government under France 2030 program.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-14
Description

Partnership with Medical Horizons S.r.l to deliver inHEART 3D cardiac modeling software solution to heart centers across Italy. Guido Osti, CEO of Medical Horizons, leads commercialization efforts.

6CHU de Bordeaux
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic hospital partner in France for clinical research and development.

inheartmedical.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish company offering ADAS 3D software for cardiac image-guided procedures including VT and AF ablation planning. Closest direct competitor to inHEART MODELS with similar pre-procedural 3D modeling, scar characterization and EAM integration approach.

TypeDirect peer
Description

Canadian cardiac MR/CT imaging software company that is both inHEART's global distribution partner and a competitor in the cardiac imaging analysis space. Offers cvi42 for cardiac MR/CT which overlaps with parts of inHEART's analytical workflow.

TypeBroad incumbent
Description

Global medtech incumbent with cardiac imaging portfolio and AI ECG interpretation via Cardiologs acquisition. Operates broadly across the cardiac care continuum and has both the imaging and AI capabilities that compete with inHEART's therapeutic and predictive roadmap.

TypeBroad incumbent
Description

Major medical imaging vendor with cardiac CT/MR portfolio and growing AI imaging capabilities. CTO Loïc Cadour's prior work on cross-platform image processing at INRIA was closely tied to cardiac imaging research with Siemens, and Siemens represents both a complementary imaging ecosystem and a competitive threat.

TypeBroad incumbent
Description

Cardiac ultrasound and imaging incumbent that previously employed CEO Todor Jeliaskov (VP at GE Ultrasound). Has scale and distribution capabilities that dwarf inHEART and could choose to enter pre-procedural cardiac modeling natively.

6Biosense Webster (Johnson & Johnson)
TypeBroad incumbent
Description

Market-leading electrophysiology company behind the Carto 3 EAM system, which inHEART MODELS integrates with. Acquired Jeliaskov's prior company NuVera Medical. Could trivially bundle a competing pre-procedural imaging module.

7Abbott
TypeBroad incumbent
Description

Medical device incumbent offering the EnSite X EAM system that integrates with inHEART. Employs several of inHEART's sales staff (Richard Bloch, Charlotte Pollmann) per previous employer history and has resources to develop competing AI imaging.

TypeBroad incumbent
Description

EP and cardiac device incumbent behind the Rhythmia HDx mapping system that inHEART integrates with. Acquired Cardiac Pathways, where consultant Dave Robinson previously worked, and has the scale to develop or acquire pre-procedural imaging capability.

9Tempus AI (Arterys)
TypeEmerging player
Description

AI-driven precision medicine company that acquired Arterys, the cardiac MR AI imaging pioneer. Provides cloud-based cardiac MR analysis with deep-learning segmentation that overlaps with parts of inHEART's automated segmentation value proposition.

TypeEmerging player
Description

AI-driven care coordination and imaging analytics company that has expanded from stroke into cardiology. While focused on acute care coordination rather than procedural planning, it shares the AI-imaging-in-clinical-workflows DNA and similar hospital SaaS commercial model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

inHEART

Cardiac Electrophysiology Softwareinheartmedical.com

inHEART develops AI-enabled digital twin software that converts cardiac CT and MR images into interactive 3D models for image-guided ablation procedures, sold to cardiac electrophysiology centers in over 40 countries.

What inHEART does

inHEART is a privately-held French medical device software company, spun off in July 2017 from IHU LIRYC (a leading cardiac electrophysiology research institute in Bordeaux), that develops an AI-enabled digital twin of the human heart for image-guided catheter ablation procedures. The company's flagship inHEART MODELS software suite ingests pre-procedural CT and MR images, applies a proprietary AI segmentation algorithm, and produces interactive 3D cardiac models that visualize scar tissue, wall thickness, and critical isthmuses, then integrates with all major electroanatomic mapping systems (Carto, Rhythmia, EnSite) for intraprocedural guidance. The technology is clinically validated by 60+ peer-reviewed publications, FDA 510(k) cleared (including a March 2024 clearance for first-of-its-kind fully automated CT segmentation), CE certified under MDR 2017/745, and registered in the UK, Australia, and Switzerland.

The commercial model is enterprise SaaS-style software licensing sold directly to tertiary and quaternary cardiac electrophysiology centers, with a quote-based pricing structure and recurring subscription mechanics. Cumulative case support exceeds 7,500 across more than 300 partner hospitals in over 40 countries, with named reference sites including MUSC Health, RHÖN KLINIKUM, Brigham and Women's, Hartford Healthcare, Hôpitaux de la Timone, and Nippon Medical School. Distribution is hybrid: direct sales in the US and EU, regional distributors (Medical Horizons in Italy), and a May 2024 global distribution agreement with Circle Cardiovascular Imaging that is the primary vehicle for Asia-Pacific and Middle East expansion.

The business is funded by approximately $15.7M in equity and grant funding across seed, Series A, and follow-on rounds, with Vesalius Biocapital IV and Elaia Partners as lead institutional investors. Revenue is not publicly disclosed. Current strategic priorities include scaling the commercial core, building predictive AI product lines for sudden cardiac death, cardioembolic stroke, and heart failure (supported by the MEDITWIN and TALENT consortia), and pursuing global regulatory clearance to enable channel-driven geographic expansion beyond the existing US and EU footprint.

inHEART firmographics

Firmographics
Name
inHEART
Legal name
inHEART
Website
https://inheartmedical.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
inHEART develops AI-enabled digital twin software that converts cardiac CT and MR images into interactive 3D models for image-guided ablation procedures, sold to cardiac electrophysiology centers in over 40 countries.
Ownership category
akta.pro rank

inHEART industry classification

Industry
Product category
Cardiac Electrophysiology Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Computer Systems Design and Related Services (54151), Diagnostic Imaging Centers (621512)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAKABAC
Electrophysiology (Heart Rhythm)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Cardiac imaging software
  • Electrophysiology solutions
  • Digital twin technology
  • Cardiac ablation planning
  • Medical imaging AI

Where inHEART is headquartered

Location

Headquarters

HQ city
Pessac
HQ country
France
HQ region
Europe

Offices2 records

Markets served

inHEART business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Software Licensing - Therapeutic Solutions: AI-driven digital twin software for image-guided cardiac ablation procedures, sold to hospitals and cardiac electrophysiology centers. Revenue derived from software licenses for the inHEART MODELS suite enabling 3D visualization and analysis for pre-procedural planning and intraprocedural guidance.
  2. Predictive Software Models (Development Stage): New product verticals under development for AI-driven predictive software models for sudden cardiac death and cardio-embolic stroke, as well as therapeutic software for heart failure patients.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

inHEART product offering

Product offering

Core offering

inHEART provides a cloud-based SaaS platform, inHEART MODELS, that uses proprietary AI segmentation algorithms to transform cardiac CT and MR images into interactive 3D digital twin models for pre-procedural planning and intraprocedural guidance of catheter ablation procedures treating arrhythmias such as ventricular tachycardia (VT), atrial fibrillation (AF), and cardioneuroablation. The software integrates with all major electroanatomic mapping (EAM) systems (Carto, Rhythmia, EnSite) and is licensed to hospitals and cardiac electrophysiology centers under a subscription-based model.

Product overview

inHEART delivers the world's most advanced AI-enabled digital twin of the heart through a cloud-based SaaS platform. The core offering is the inHEART MODELS software suite that creates interactive 3D models from CT and MR images for image-guided cardiac ablation planning. The platform includes AI-driven automated segmentation capabilities and integrates with all major electroanatomic mapping (EAM) systems. Current commercial products include therapeutic solutions for VT ablation, atrial fibrillation, and cardioneural ablation. Development underway includes predictive models for sudden cardiac death, cardio-embolic stroke, and heart failure. The company operates through the MEDITWIN and TALENT consortia for preventive cardiac care solutions. Available in US (FDA 510(k) cleared) and EU (CE MDR certified) markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • inHEART MODELS (Digital Twin of the Heart) AI-enabled cloud-based software suite that creates interactive 3D digital twin models of the heart from CT and MR images, providing unprecedented anatomical detail including scar visualization, wall thickness, tissue characteristics, and critical isthmus identification for personalized image-guided cardiac ablation planning. Licensed to hospitals and cardiac electrophysiology centers on a subscription basis and integrates with all major electroanatomic mapping (EAM) systems including Carto, Rhythmia, and EnSite.

Quantifiable outcome

  • Reduces procedure time by 60% (from 5 hours to less than 2 hours)
  • +2 more outcomes

Companies that use inHEART

Customer profile

Named customers10 records

Segments2 records

Ideal customer profiles2 records

inHEART technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

inHEART partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, regional and minor.

  • Circle Cardiovascular ImagingcoreChannel Partner/ Reseller/ Distributor · 16 May 2024Global distribution agreement enabling Circle to promote and market inHEART's AI-enabled digital twin through Circle's worldwide sales network. Partnership enables rapid global commercialization and particularly strengthens Asia-Pacific market presence.
  • Dassault Systèmes (MEDITWIN Consortium)coreStrategic or Co-development Partner · 11 January 2024MEDITWIN is a 5-year multidisciplinary consortium (2024-2029) evaluating personalized digital twins in healthcare. inHEART focuses on sudden cardiac death prevention using AI-based digital twin technology for risk stratification. Supported by French government.
  • IHU LiryccoreStrategic or Co-development Partner · 11 January 2024inHEART is a spin-off company of IHU Liryc, the cardiac electrophysiology institute. Long-standing research and development partnership for cardiac imaging innovation.
  • TALENT ConsortiumcoreStrategic or Co-development Partner · 11 January 2024Collaboration with 9 academic, hospital, and industrial partners to screen for Cardioembolic Stroke risk using AI-based digital twins via chest CT and ECG. Supported by French government under France 2030 program.
  • Medical HorizonsregionalChannel Partner/ Reseller/ Distributor · 14 June 2022Partnership with Medical Horizons S.r.l to deliver inHEART 3D cardiac modeling software solution to heart centers across Italy. Guido Osti, CEO of Medical Horizons, leads commercialization efforts.
  • CHU de BordeauxminorStrategic or Co-development PartnerAcademic hospital partner in France for clinical research and development.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

inHEART competitors and assessment

Company assessment

Direct peers

  • Galgo Medical (ADAS 3D): Spanish company offering ADAS 3D software for cardiac image-guided procedures including VT and AF ablation planning. Closest direct competitor to inHEART MODELS with similar pre-procedural 3D modeling, scar characterization and EAM integration approach.
  • Circle Cardiovascular Imaging: Canadian cardiac MR/CT imaging software company that is both inHEART's global distribution partner and a competitor in the cardiac imaging analysis space. Offers cvi42 for cardiac MR/CT which overlaps with parts of inHEART's analytical workflow.

Broad incumbents

  • Philips (Cardiologs): Global medtech incumbent with cardiac imaging portfolio and AI ECG interpretation via Cardiologs acquisition. Operates broadly across the cardiac care continuum and has both the imaging and AI capabilities that compete with inHEART's therapeutic and predictive roadmap.
  • Siemens Healthineers: Major medical imaging vendor with cardiac CT/MR portfolio and growing AI imaging capabilities. CTO Loïc Cadour's prior work on cross-platform image processing at INRIA was closely tied to cardiac imaging research with Siemens, and Siemens represents both a complementary imaging ecosystem and a competitive threat.
  • GE HealthCare: Cardiac ultrasound and imaging incumbent that previously employed CEO Todor Jeliaskov (VP at GE Ultrasound). Has scale and distribution capabilities that dwarf inHEART and could choose to enter pre-procedural cardiac modeling natively.
  • Biosense Webster (Johnson & Johnson): Market-leading electrophysiology company behind the Carto 3 EAM system, which inHEART MODELS integrates with. Acquired Jeliaskov's prior company NuVera Medical. Could trivially bundle a competing pre-procedural imaging module.
  • Abbott: Medical device incumbent offering the EnSite X EAM system that integrates with inHEART. Employs several of inHEART's sales staff (Richard Bloch, Charlotte Pollmann) per previous employer history and has resources to develop competing AI imaging.
  • Boston Scientific: EP and cardiac device incumbent behind the Rhythmia HDx mapping system that inHEART integrates with. Acquired Cardiac Pathways, where consultant Dave Robinson previously worked, and has the scale to develop or acquire pre-procedural imaging capability.

Emerging players

  • Tempus AI (Arterys): AI-driven precision medicine company that acquired Arterys, the cardiac MR AI imaging pioneer. Provides cloud-based cardiac MR analysis with deep-learning segmentation that overlaps with parts of inHEART's automated segmentation value proposition.
  • Viz.ai: AI-driven care coordination and imaging analytics company that has expanded from stroke into cardiology. While focused on acute care coordination rather than procedural planning, it shares the AI-imaging-in-clinical-workflows DNA and similar hospital SaaS commercial model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

inHEART social profiles

Digital presence

inHEART compliance and trust

Trust signal

Compliance8 records

inHEART financial estimates

Financial estimate

Revenue estimate

Valuation estimate

inHEART leadership team

Management profile

Number of profiles

Profiles11 records

inHEART subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

inHEART funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

inHEART M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about inHEART

What does inHEART do?

inHEART provides a cloud-based SaaS platform, inHEART MODELS, that uses proprietary AI segmentation algorithms to transform cardiac CT and MR images into interactive 3D digital twin models for pre-procedural planning and intraprocedural guidance of catheter ablation procedures treating arrhythmias such as ventricular tachycardia (VT), atrial fibrillation (AF), and cardioneuroablation. The software integrates with all major electroanatomic mapping (EAM) systems (Carto, Rhythmia, EnSite) and is licensed to hospitals and cardiac electrophysiology centers under a subscription-based model.

Is inHEART a public or private company?

inHEART is a private company. It is classified as venture growth investor backed and is currently operating.

When was inHEART founded?

inHEART was founded in 2017. It employs 11 to 50 people.

Where is inHEART based?

inHEART is headquartered in Pessac, France, in the Europe region.

How does inHEART make money?

Two revenue lines are on record. Software Licensing - Therapeutic Solutions are the primary driver. The others are predictive Software Models (Development Stage).

Who are inHEART's main competitors?

Direct peers on record are Galgo Medical (ADAS 3D) and Circle Cardiovascular Imaging. Broad incumbents are Philips (Cardiologs), Siemens Healthineers, GE HealthCare, Biosense Webster (Johnson & Johnson), Abbott and Boston Scientific. Emerging players are Tempus AI (Arterys) and Viz.ai.

Does inHEART have an API?

No public API is recorded for inHEART.

What industry is inHEART in?

inHEART's product category is Cardiac Electrophysiology Software. Its primary akta.pro industry code is HLAKABAC, Electrophysiology (Heart Rhythm), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InheartmedicalinHEARTinHEART closed a 750k€ funding round with SWEN Capital Partners to accelerate its AI-driven digital twin of the heart. The investment will support development of its imaging platform for diagnosing and treating cardiac arrhythmias. The company aims to expand its reach and enhance technology access for healthcare professionals and patients.PR NewswireCircle Cardiovascular Imaging Partners with inHEART to Distribute AI-Driven Digital Twin of the Heart for Advanced Cardiac Procedural Planning in the Electrophysiology LabCircle Cardiovascular Imaging and inHEART announced a global distribution agreement at the Heart Rhythm Society Conference, enabling Circle to promote and market inHEART's AI-driven digital twin of the heart through Circle's worldwide sales network. The partnership aims to accelerate inHEART's global commercialization, particularly in the Asia-Pacific markets, while expanding Circle's cardiac imaging capabilities into electrophysiology pre-procedural planning. Both companies characterize the agreement as a strategic fit to improve patient access to advanced cardiac imaging and clinical outcomes.Pulse 2.0inHEART: Medical Device Company Raises $11 MillionMedical device company inHEART has raised $11 million in a funding round led by Vesalius Biocapital IV and co-led by Elaia Partners to expand its AI-driven digital twin technology for heart conditions. The capital will support the commercial growth of its therapeutic software for cardiac ablation procedures and accelerate the development of predictive models for heart failure, sudden cardiac death, and cardio-embolic stroke. Currently available in the US and EU, the company plans to establish a global distribution network to further scale its operations.TheRecursive.cominHeart Secures $11M to Fast-track Innovation in Cardiac SolutionsBulgarian-led inHeart secured $11 million in funding led by Vesalius Biocapital IV and co-led by Elaia Partners to advance its AI-enabled cardiac digital twin technology. The capital will be used to drive commercial growth for cardiac ablation procedures and develop predictive models for heart failure and stroke. Currently available in the US and EU, the company plans to establish a global distribution network.FinSMEsInheart Raises USD11M in FundingInheart, a medical device company based in Pessac, France, raised USD11M in funding to support the commercial expansion of its AI-driven digital twin of the heart. The funding round was led by Vesalius Biocapital IV and included participation from multiple investors, with the funds aimed at the US, EU, Asia Pacific, and Middle East markets. Inheart's CEO emphasized the potential of this funding to improve the efficiency and effectiveness of cardiac care using AI technology.PR NewswireINHEART RAISES $11M TO ACCELERATE DEVELOPMENT & DEPLOYMENT OF NOVEL THERAPEUTIC, PREDICTIVE, AND SCREENING CARDIAC SOLUTIONSinHEART raised $11M led by Vesalius Biocapital IV to expand its AI-driven cardiac digital twin and develop predictive models for heart failure and sudden cardiac death. The funding supports commercial growth in the US, EU, Asia Pacific, and Middle East, with plans for a global distribution network.InheartmedicalinHEARTinHEART, a medical device company based in Cambridge, MA, has raised $11 million in a funding round led by Vesalius Biocapital IV and co-led by Elaia Partners to support commercial expansion and software development. The capital will drive growth of its AI-driven digital twin of the heart for cardiac ablation procedures in the US, EU, Asia Pacific, and Middle East markets while advancing predictive models for heart failure and stroke.Silicon Valley JournalsinHEART raised $11m in a funding roundinHEART has secured $11 million in funding led by Vesalius Biocapital IV and co-led by Elaia Partners to expand its AI-driven cardiac care solutions. The capital will support the commercial rollout of its digital twin heart product across the US, EU, Asia Pacific, and the Middle East, while also funding further development of predictive models for heart failure and stroke.PR NewswireINHEART RAISES $11M TO ACCELERATE DEVELOPMENT & DEPLOYMENT OF NOVEL THERAPEUTIC, PREDICTIVE, AND SCREENING CARDIAC SOLUTIONSinHEART raised $11 million in a funding round led by Vesalius Biocapital IV and co-led by Elaia Partners to accelerate the commercial expansion of its AI-driven digital twin of the heart. The capital will support growth in the US, EU, Asia Pacific, and Middle East markets while advancing the development of predictive software models for conditions such as heart failure and stroke.PR NewswireinHEART RECEIVES FDA CLEARANCE FOR ADVANCED AI-DRIVEN SOFTWARE MODULE THAT OPTIMIZES THE CREATION OF 3D MODELS OF THE HEARTinHEART, a medical device company with operations in Cambridge, Massachusetts and Bordeaux, France, has received FDA 510(k) clearance for its AI software module that automates the segmentation of CT images to create 3D cardiac models. The new module enables the company to deliver its digital twin solution to physicians with greater speed and efficiency, previously available only in the EU, and will now be deployed in US hospitals. Clinical evaluations indicate the technology can reduce ventricular tachycardia (VT) procedure times by 60% (from 5 hours to under 2 hours) and reduce VT recurrence rates by 38% compared to conventional ablation strategies.